You are here

Article Text

Article menu
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Efficacy of low-dose topical mitomycin C treatment for primary acquired melanosis
  1. Susan Hung1,
  2. Tony Tsai2,
  3. David Hwang3,
  4. Joan O’Brien4
  1. 1
    University of California, San Francisco, 320 Lake Merced Blvd, #12, Daly City, California, 94015, USA
  2. 2
    University of California, San Francisco, Ophthalmology, 3939 J St. #104, Sacramento, California, 95819, USA
  3. 3
    University of California, San Francisco, Ophthalmology, Box 0730, 10 Kirkham K207, UCSF, San Francisco, California, 94143, USA
  4. 4
    University of California, San Francisco, Ophthalmology, Box 0730, 10 Koret Way K231, UCSF, San Francisco, California, 94143, USA
  1. Joan O’Brien, ObrienJ{at}vision.ucsf.edu

Summary

Primary acquired melanosis (PAM) with atypical cytological features has nearly a 50% chance of progressing to malignant melanoma. Surgical excision with cryotherapy has been the mainstay of treatment, but topical treatment with mitomycin C (MMC) is an increasingly common alternative treatment. Since PAM is relatively rare and MMC is a new treatment option, publications are limited to case reports and a few small series. Optimum doses, duration and timing of treatment cycles have not been established. Two patients were diagnosed with PAM with atypia and were treated with either primary or adjuvant treatment of 0.02% MMC for approximately 10 days for three cycles, which is the lowest dose protocol published to date for the treatment of PAM. Both patients showed stable partial response and only experienced temporary ocular drug toxicity.

https://doi.org/10.1136/bcr.12.2008.1409

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Hung and Tsai contributed equally to this publication.

    • Competing interests: none.

    • Patient consent: Patient/guardian consent was obtained for publication.